BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes

by Cooper, Zachary A, Frederick, Dennie T, Juneja, Vikram R, Sullivan, Ryan J, Lawrence, Donald P, Piris, Adriano, Sharpe, Arlene H, Fisher, David E, Flaherty, Keith T, Wargo, Jennifer A
Published 2014

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma

by Kim, Teresa, Amaria, Rodabe N., Spencer, Christine, Reuben, Alexandre, Cooper, Zachary A., Wargo, Jennifer A.
Published 2015

PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation

by Sabbatino, Francesco, Wang, Yangyang, Wang, Xinhui, Flaherty, Keith T., Yu, Ling, Pepin, David, Scognamiglio, Giosue', Pepe, Stefano, Kirkwood, John M., Cooper, Zachary A., Frederick, Dennie T., Wargo, Jennifer A., Ferrone, Soldano, Ferrone, Cristina R.
Published 2014

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation

by Kim, Hyungsoo, Frederick, Dennie T., Levesque, Mitchell P., Cooper, Zachary A., Feng, Yongmei, Krepler, Clemens, Brill, Laurence, Samuels, Yardena, Hayward, Nicholas K., Perlina, Ally, Piris, Adriano, Zhang, Tongwu, Halaban, Ruth, Herlyn, Meenhard M., Brown, Kevin M., Wargo, Jennifer A., Dummer, Reinhard, Flaherty, Keith T., Ronai, Ze’ev A.
Published 2016

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

by Geller, Leore T., Barzily-Rokni, Michal, Danino, Tal, Jonas, Oliver H., Shental, Noam, Nejman, Deborah, Gavert, Nancy, Zwang, Yaara, Cooper, Zachary A., Shee, Kevin, Thaiss, Christoph A., Reuben, Alexandre, Livny, Jonathan, Avraham, Roi, Frederick, Dennie T., Ligorio, Matteo, Chatman, Kelly, Johnston, Stephen E., Mosher, Carrie M., Brandis, Alexander, Fuks, Garold, Gurbatri, Candice, Gopalakrishnan, Vancheswaran, Kim, Michael, Hurd, Mark W., Katz, Matthew, Fleming, Jason, Maitra, Anirban, Smith, David A., Skalak, Matthew T., Bu, Jeffrey, Michaud, Monia, Trauger, Sunia A., Barshack, Iris, Golan, Talia, Sandbank, Judith, Flaherty, Keith T., Mandinova, Anna, Garrett, Wendy S., Thayer, Sarah P., Ferrone, Cristina R., Huttenhower, Curtis, Bhatia, Sangeeta N., Gevers, Dirk, Wargo, Jennifer A., Golub, Todd R., Straussman, Ravid
Published 2020

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma

by Cooper, Zachary A., Reuben, Alexandre, Spencer, Christine N., Prieto, Peter A., Austin-Breneman, Jacob L., Jiang, Hong, Haymaker, Cara, Gopalakrishnan, Vancheswaran, Tetzlaff, Michael T., Frederick, Dennie T., Sullivan, Ryan J., Amaria, Rodabe N., Patel, Sapna P., Hwu, Patrick, Woodman, Scott E., Glitza, Isabella C., Diab, Adi, Vence, Luis M., Rodriguez-Canales, Jaime, Parra, Edwin R., Wistuba, Ignacio I., Coussens, Lisa M., Sharpe, Arlene H., Flaherty, Keith T., Gershenwald, Jeffrey E., Chin, Lynda, Davies, Michael A., Clise-Dwyer, Karen, Allison, James P., Sharma, Padmanee, Wargo, Jennifer A.
Published 2016

Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

by Straussman, Ravid, Morikawa, Teppei, Shee, Kevin, Barzily-Rokni, Michal, Qian, Zhi Rong, Du, Jinyan, Davis, Ashli, Mongare, Margaret M., Gould, Joshua, Frederick, Dennie T., Cooper, Zachary A., Chapman, Paul B., Solit, David B., Ribas, Antoni, Lo, Roger S., Flaherty, Keith T., Ogino, Shuji, Wargo, Jennifer A., Golub, Todd R.
Published 2014

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment

by Friedman, Adam A., Amzallag, Arnaud, Pruteanu-Malinici, Iulian, Baniya, Subash, Cooper, Zachary A., Piris, Adriano, Hargreaves, Leeza, Igras, Vivien, Frederick, Dennie T., Lawrence, Donald P., Haber, Daniel A., Flaherty, Keith T., Wargo, Jennifer A., Ramaswamy, Sridhar, Benes, Cyril H., Fisher, David E.
Published 2015

Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics

by Frederick, Dennie T., Salas Fragomeni, Roberto A., Schalck, Aislyn, Ferreiro-Neira, Isabel, Hoff, Taylor, Cooper, Zachary A., Haq, Rizwan, Panka, David J., Kwong, Lawrence N., Davies, Michael A., Cusack, James C., Flaherty, Keith T., Fisher, David E., Mier, James W., Wargo, Jennifer A., Sullivan, Ryan J.
Published 2014